|
|
|
|
Halozyme Therapeutics Reports Fourth Quarter and Year End 2009 Financial Results
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery...
|
|
|
US teams partner up to sequence difficult breast cancers
Life Technologies is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumours have progressed despite multiple other therapies.
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resour
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision...
|
|
|
Halozyme Therapeutics Reports Fourth Quarter and Year End 2009 Financial Results
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) -- Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) -- Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents per share,...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) -- Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) -- Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
(AP) SAN DIEGO - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
Halozyme Therapeutics reports smaller loss due to $5.8 million in payments from Roche, Baxter Buzz up!Companies: Topics: Related Quotes {'s' : 'halo','k' : 'c10,l10,p20,t10','o' : '','j' : ''} SAN DIEGO (AP) -- Biotechnology company Halozyme Therapeutics Inc...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
ET SAN DIEGO Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGOBiotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14 cents...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO (AP) - Biotechnology company Halozyme Therapeutics Inc.said Friday that it trimmed its fourth-quarter loss with help from a large payment from its partner Baxter International and Swiss drug maker Roche. Halozyme said it lost $12.7 million, or 14...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
Halozyme said it lost $12.7 million, or 14 cents per share, compared with a loss of $16.8 million, or 21 cents per share, in the same quarter a year before.Revenue more than doubled to $6.4 million from $3.1 million. The latest quarter's results included ...
|
|
|
Halozyme narrows 4Q loss due to Hylenex payment
SAN DIEGO -- Halozyme said it lost $12.7 million, or 14 cents per share, compared with a loss of $16.8 million, or 21 cents per share, in the same quarter a year before.Revenue more than doubled to $6.4 million from $3.1 million. The latest quarter's...
|
